Eleven compounds were isolated from the methanolic extract of the leaves of Solanum erianthum D. Don, including five -linolenic acid analogs, -linolenic acid (1), 13S-hydroxy-9(Z),11(E)-octadecadienoic acid (2), 9S-hydroxy-10(E),12(Z), 15(Z)-octadectrienoic acid (3), 9(Z),11(E)-octadecadienoic acid (4), and octadecanoic acid (5); two benzofuran-type lactones, loliolide (6) and dihydroactinidiolide (7); two steroidal alkaloids, solasonine (8) and solamargine (9); a flavonol glycoside, camelliaside C (10); and a flavone, 5-methoxy-(3'',4''-dihydro-3'',4''-diacetoxy)-2'',2''-dimethylpyrano-(7,8:5'',6'')-flavone (11). Among these isolated compounds, 9 showed the most potent activity against HBsAg, with an IC 50 of 1.57 M, followed by 8 (IC 50 is 5.89 M). In the testing against HBeAg, 11 was the only active compound with an IC 50 of 36.11 M. Compound 9 also revealed strong inhibition of DNA replication towards HBV and its IC 50 was 2.17 M. However, -linolenic acid (1) showed a prominent selected index (SI), both in anti-HBsAg and inhibition of DNA replication with SI values of 7.75 and 7.18, respectively. This is the first report that unsaturated fatty acid 1, steroidal alkaloid glycoside 9 and flavone 11, all showed excellent activity against HBV. These results provide lead candidates in the development of anti-HBV drugs from natural sources.
Hepatitis B virus (HBV) infection is a severe health problem worldwide. There is still no satisfactory therapy for HBV infection because of higher side effects and lower efficacy of the currently used clinical drugs. However, a variety of natural products derived from medicinal plants provide a large reservoir of potentially bioactive agents with anti-HBV activity, for instance, Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. [1] . Several Solanum species (Solanaceae) are traditionally used for treatment of HBV infection, such as S. incanum, S. capsicastrum and S. aculeatissimum. In an attempt to discover novel resources of medicinal plants and to investigate the mechanism of anti-HBV activity, we selected S. indica, S. torvum and S. erianthum as target materials. The results showed that the methanolic extract from S. erianthum possessed the most prominent activity in the evaluation of anti-HBV effect.
S. erianthum D. Don, a shrub or small tree native to South America, is now widespread in tropical Asia and Oceania. In Taiwan, this plant, also known as S. verbascifolium Linn,, is found commonly along roadsides and river banks from 300-2100 m [2] . Roots and leaves of this plant have been using as folk medicine for treatment of metrorrhagia, edema, gout, carbuncles, eczema, toothache, dermatitis and bacterial infection [3] [4] [5] . Cumulative phytochemical research on this species has resulted in the isolation of steroidal alkaloid glycosides [6] , a cinnamide derivative [7] and flavonol glycosides [8] . The present study has led to the isolation of eleven constituents ( Figure 1 ). The compounds characterized were five -linolenic acids (1-5), two monoterpenes (6-7), two steroidal alkaloid glycosides (8-9), a flavonol glycoside (10) and a flavone (11) derivative. α-Linolenic acids are part of the monomers in the formation of cutin on the surface of leaves. Compounds 6 and 7 have been found in both higher plants and algae, and have been synthesized [9] [10] [11] . The identity of each compound was determined by comparison with literature spectral data. Compounds 6, 7, 10, and 11 were first found from Solanaceous plants, but have been isolated from other plants [12] [13] [14] .
Of the compounds isolated, solamargine (9) showed significant anti-HBsAg activity and an inhibitory effect on DNA replication, with IC 50 values of 1.57 M and 2.17 M, respectively. Compound 11 showed moderate activity in anti-HBeAg testing, with an IC 50 of 36.11 M. The IC 50 for -linolenic acid (1) was 23.35 M against HBsAg, and 25.18 M in the inhibition test for DNA replication. The SI of 1 was 7.75 in the HBsAg and 7.18 in the DNA replication tests.
Inhibition to HBV, anti-HBsAg, anti-HBeAg and DNA replication tests were employed; the results are tabulated in Table 1 . Fluorouracil (5-FU) and lamivudine (3TC) were used as the positive controls for cytotoxic and DNA replication evaluation, respectively. Steroidal alkaloids 8 and 9 were the most active constituents against the surface antigen of HBV. Structurally, 8 and 9 differ in their sugar moieties, while sharing the same solasodine nucleus. Flavone derivative 11 showed moderate activity, though this class of compound has previously demonstrated promising activity against HBV [15] . α-Linolenic acid (1) also revealed moderate activity, with an IC 50 of 23.35 M against HBsAg, while its analogs, either oxidative or reductive, i.e. 2-5, had weak or no activity. Monoterpenes, such as 6 and 7, together with flavonol glycoside (10), were all inactive. Surprisingly, 11 is the only molecule that is active against HBeAg among these isolates. In addition, solamargine (9) demonstrated significant activity in the inhibition to DNA replication test and was almost comparable with lamivudine, a clinical drug used to combat hepatitis B virus. Compounds 1 and 11 were potent in the DNA replication test as well, though weaker than 9. Moreover, in order to evaluate the respective toxicity to the HepG2 2.2.15 cell line and assess the potential to be a lead molecule against HBV, the SI value was calculated as TC 50 /IC 50 and shown in Table 2 . Compounds 1 and 9 showed greater SI compared with their corresponding analogs, 3 and 8. Compound 11 was almost equal to that of 1 in the evaluation of anti-HBsAg. Compound 1 is potentially higher than 9 and 11, whose SI values are almost identical in the inhibition of DNA replication. Also, for compounds 1, 9, and 11 , the DNA replication and HBsAg levels were significantly reduced in a dose-dependent manner, as shown in Figures 2 and 3 . However, compounds 1 and 11 showed weak activity for inhibition of HBeAg secretion, while 9 revealed a stimulatory effect, shown in Figure 4 . As the regulation of DNA replication is quite different from that of the expression of HBV surface antigen, 1, 9 and 11 inhibited not only HBV DNA replication, but also secretion of viral surface antigen. Reversetranscription PCR analysis of HBV mRNA level will be conducted in order to clarify the possibility of interference of the transcription process. This finding indicates that 1, 9, and 11 could be lead molecules in the search for novel constituents for the treatment of HBV with multiple mechanisms. It is reported that α-linolenic acid reduced hepatitis C virus (HCV) RNA levels at a concentration of 100 µM, while saturated counterparts were not active [16] . cells were treated with 1 from 0.625 to 2.5 µg/mL and with 9 and 11 from 2.5 to 10 µg/mL for 3 days, respectively. The media were collected at day 3 then the HBeAg was quantified using the EIA kit. The data are presented as mean ± S.E. The significant difference was set at *P<0.05; **P<0.01.
